EXT proteins: Role in heparan sulfate Assembly and in Tumor biology by Sembajwe, Lawrence Fred
EXT proteins: Role in heparan
sulfate Assembly and in Tumor
biology
Lawrence Fred Sembajwe
University of Bergen, Norway
2018
Thesis for the Degree of Philosophiae Doctor (PhD)
at the University of Bergen
Avhandling for graden philosophiae doctor (ph.d )
ved Universitetet i ergen
.
2017
Dato for disputas: 1111
EXT proteins: Role in heparan sulfate
Assembly and in Tumor biology
Lawrence Fred Sembajwe
2018
Thesis for the De ree of Philosophiae Doctor (PhD)
Date of defence: 24.08.2018
The material in this publication is covered by the provisions of the Copyright Act.
Print:     Skipnes Kommunikasjon / University of Bergen
Title: EXT proteins: Role in heparan sulfate Assembly and in Tumor biology
© Copyright Lawrence Fred Sembajwe
Name:        Lawrence Fred Sembajwe
Year:          2018
 3 
Scientific environment  
The work outlined in this thesis was done under the matrix biology group at the 
Department of Biomedicine – University of Bergen, under the supervision of Prof. 
Marion Kusche-Gullberg. Most of the experiments were conducted using facilities at 
the department such as equipment in the general laboratory and the cell-culture room. 
Flow cytometry experiments were done at the Department of Clinical Laboratory and 




This work was funded by University of Bergen-quota program, Norwegian Cancer 
Society and Meltzer foundation travel grant. 
I am very grateful for the enduring and constant guidance that I have been receiving 
from my supervisor – Prof. Marion Kusche-Gullberg throughout the duration of my 
PhD studies.  
I want also to express my sincere gratitude to the people who helped me with the 
various experiments and co-authored some of the manuscripts or articles with me: I 
thank Kirankumar Katta for his contribution to the first two papers in this dissertation. 
I am especially very thankful for the services of Mona Gronning from the first time I 
entered the Matrix Biology Lab to completion of my research work. I doubt if this work 
would have been accomplished without her dedicated technical services and advice. 
I also thank all the other members of the Matrix biology group under the leadership of 
Prof. Donald Gullberg at the Department of Biomedicine, for their constructive 
criticism during the numerous presentations made in our routine meetings.  
I am also thankful for the friendship and cooperation that I have experienced working 
near some people from the Neuroscience group. I will always remember their kindness 
and funny little jokes! 
Finally, I dedicate this dissertation to my Mother – Teopista Nantume for her support 
throughout my many years of education. It seems her ‘Joker’ has made yet another 






C1/C2: Constant or Conserved regions 1 and 2 
CS: Chondroitin sulfate 
DEAE: Diethyl amino ethyl 
DMEM: Dulbecco’s modified Eagles medium 
ECM: Extracellular matrix 
EFYA: Amino acids – Glutamine, Phenylalanine, Tyrosine and Alanine 
ER: Estrogen receptor 
ERK: Extracellular regulated kinase 
EXT: Exostosin 
EXTL: Exostosin like 
FGF: Fibroblast growth factor 
GAGs: Glycosaminoglycans 
GlcA: Glucuronic acid 
GlcNAc: N-acetylglucosamine 
Gt: Gene trap  
HA: Hyaluronan 
HAS: Hyaluronan Synthase 
HER2: Human epidermal growth factor receptor-2 
HPRT: Hypoxanthine guanine phosphoribosyl transferase   
HS: Heparan sulfate 
HSPG: Heparan sulfate proteoglycan 
HPLC: High performance liquid chromatography 
KO: Knockout 
MAPK: Mitogen Activated Protein Kinase 
MO: Multiple Osteochondromas 
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NSCLC: Non-small cell lung cancer  
PBS: Phosphate buffered saline 
PDZ: Postsynaptic Density (PSD-9) protein/, Drosophila melanogaster-Disc-Large/, Zona 
Occludens 
PG: Proteoglycan 
POLR2F: RNA polymerase II subunit F  
PR: Progesterone receptor 
RPMI: Roswell Park Memorial Institute 
RTK: Receptor Tyrosine Kinase 
RTqPCR: Reverse transcriptase, quantitative real time polymerase chain reaction 
SDS-PAGE: Sodium dodecyl sulfate-Polyacrylamide gel electrophoresis 
VEGFA: Vascular Endothelial Growth Factor-A 
VEGFR: Vascular Endothelial Growth Factor Receptor 
Wnt: Wint 
Wt: Wild type  
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Abstract 
The exostosin family of proteins is necessary for heparan sulfate biosynthesis. Heparan 
sulfate polysaccharide biosynthesis is one of several different forms of protein-
glycosylation processes that take place in the Golgi apparatus. Heparan sulfate 
modification of a few selected proteins results into the formation of heparan sulfate 
proteoglycans that are found on cell surfaces, inside the cell and in extracellular 
matrices. The heparan sulfate chains of the proteoglycans bind a wide range of 
molecules such as growth factors, serine protease inhibitors and extracellular matrix 
proteins, thereby influencing a number of cellular processes including cell-signaling 
and inter-cellular communication. The heparan sulfate chains are important in 
development, homeostasis and in pathogenesis of various diseases including cancer. 
Whereas the activity of the exostosin family of proteins is deemed pivotal for functional 
heparan sulfate chains, the roles of each of the exostosin members and their 
mechanisms of action or interaction are not well known. Thus, in this thesis we aimed 
at generating more knowledge about the role of the exostosin proteins. We used gene 
expression profiling techniques to study the expression of exostosin genes in both 
normal and cancer cell-lines. We analyzed the effect of exostosin-1 deficiency in 
stromal fibroblasts on gene expression in co-cultured A549-carcinoma cells. Our data 
suggests a new potential role of the exostosin-1 protein in influencing tumor behavior 
through Tgf-β1. We also investigated the link between the expression levels of the 
exostosin family of genes and HS-structure in non-malignant and breast cancer 
epithelial cell-lines. The results of this investigation showed no direct correlation 
between gene expression of the exostosin family members and heparan sulfate-
structure. In addition, we studied the effect of pH on the in vitro glycosyltransferase 
activity of Exostosin-1 and Exostosin-2 proteins. We observed decreased enzyme 
activities with reduced pH values.  
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1.1 General background  
Heparan sulfate (HS), a polysaccharide closely related to heparin, has been implied in a large 
number of functions in normal physiology and in pathology (Bishop, Schuksz, & Esko, 2007; 
Gallagher, 2015; J. P. Li & Kusche-Gullberg, 2016). HS polysaccharide chains are covalently 
attached to different proteins in a proteoglycan (PG) molecule (Couchman, 2010). HSPGs are 
present throughout evolution and are synthesized by every mammalian cell. HSPGs are very 
important for normal development and hemostasis through their roles in mediating protein-
protein interactions between for example signaling factors and their cognate receptors (Bishop 
et al., 2007). Heparin is a highly sulfated variant of HS synthesized by a subset of mast cells 
(Casu, Naggi, & Torri, 2015; Kolset & Pejler, 2011). Heparin has since 1930s been used 
clinically as an anticoagulant (Casu et al., 2015). The physiological role of heparin in the 
mammalian body is not known and its function is probably not related to coagulation. 
HSPGs are via their HS chains involved in a diverse number of biological events 
related to intracellular signaling, cell-cell interactions and tissue morphogenesis (Bishop et al., 
2007; Blanchette, Thackeray, Perrat, Hekimi, & Benard, 2017; Gallagher, 2015; J. P. Li & 
Kusche-Gullberg, 2016). In this way, the HS chains influence not only normal cell 
homeostasis but also the behavior of cancer cells (Lim, Multhaupt, & Couchman, 2015). The 
diverse functions of HS are dependent on the fine structure of HS chains that are formed during 
its biosynthesis. HS biosynthesis involves a number of different enzymes with cell and tissue 
specific expression that is believed to determine the HS structure (J. P. Li & Kusche-Gullberg, 
2016).  
The HSPGs constitute an important part of the extracellular matrix (ECM), either in 
the pericellular environment of cells or as solubilized and freely secreted molecules. HSPGs 
such as agrin, collagen XVIII and perlecan are generally found in the basement membrane (a 
specialized ECM) but may also be secreted into the interstitial fluid (McCarthy, 2015). The 
shedding of cell surface HSPGs by proteolytic enzymes generates soluble HSPGs that can 
inhibit protein interactions at the cell surface or execute their function somewhere else 
(Manon-Jensen, Itoh, & Couchman, 2010).  
The studies presented in this thesis focused on the HS chain elongating enzymes belonging to 
the so-called exostosin family of proteins and how they influence HS structure and function 
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in tumor biology. In order to dissect the role of HS chains in pathological conditions, their 
mode of function in normal physiology need to be well understood. Therefore, we also studied 
the glycosyltransferase activities of EXT proteins under varying pH conditions. 
 
1.2 Proteoglycans 
Proteoglycans (PGs) consist of one or more unbranched sulfated polysaccharide chains called 
glycosaminoglycans (GAGs) covalently attached to a core protein (J. P. Li & Kusche-
Gullberg, 2016). 
1.2.1 Glycosaminoglycans [GAGs] 
Glycosaminoglycans (GAGs) are long and unbranched polysaccharides consisting of 
repeating disaccharides, composed of alternating hexuronic acid: glucuronic acid (GlcA) or 
iduronic acid (IdoA) and hexosamine: glucosamine (GlcNAc) or galactosamine (GalNAc) 
(Prydz & Dalen, 2000). Depending on the nature of the repeating disaccharides, GAGs are 
divided into four main groups: heparan sulfate (HS), chondroitin/dermatan sulfate (CS/DS), 
hyaluronan/ hyaluronic acid (HA) and keratan sulfate (KS) (Figure 1). HS chains consist of 
an alternating sequence of GlcNAc and uronic acid (GlcA or IdoA) (Prydz, 2015). The 
repeating disaccharide in CS is made of GalNAc and GlcA. A CS chain containing GlcA 
residues that have been epimerized to IdoA is called DS (Prydz & Dalen, 2000). HA is 
composed of repeating GlcA and GlcNAc units.  Keratan sulfate lacks the hexuronic acid 
moiety and is composed of alternating galactose and GlcNAc units (Prydz, 2015). With the 
exception of HA, all the other GAGs are sulfated and found covalently attached to a core-
protein forming a PG structure. Hybrid PGs are formed when different types of GAG-chains 
are attached to the same core protein (Couchman, 2010).  
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Figure 1. Structure of the different glycosaminoglycan chains. The structure of the repeating 
disaccharides in the different types of glycosaminoglycan chains is drawn without sulphation. 
The different sulphation positions in each GAG are marked by encircling with a dashed red 
line. Adopted from (Prydz & Dalen, 2000) with permission.  
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1.2.2 Heparan sulfate proteoglycans (HSPGs)   
Heparan sulfate proteoglycans are found distributed on the cell surface with members such as 
syndecans and glypicans (Multhaupt, Leitinger, Gullberg, & Couchman, 2016), in the ECM 
(e.g. perlecan and collagen XVIII) (Iozzo, Zoeller, & Nystrom, 2009) and intracellular 
(serglycin) (Kolset, Prydz, & Pejler, 2004). Collagen XVIII and the cell surface associated PG 
CD44 are referred to as ‘part-time proteoglycans’ because they exist with or without 
covalently added HS chains (Fjeldstad & Kolset, 2005; Ponta, Sherman, & Herrlich, 2003).  
The major cell surface proteoglycans - syndecans and glypicans differ in the nature of their 
association with the cell membrane (Fig. 2): the syndecans are transmembrane PGs, 
(Couchman, 2010) whereas the glypicans are anchored onto the cell membrane by a short 
glycosylphosphatidylinositol (GPI) anchor (Filmus, Capurro, & Rast, 2008). Perlecan is 
primarily found in the basement membrane but may also exist outside the basement membrane 
in the interstitial connective tissue. Perlecan has a complex core protein with HS chains 
covalently attached toward the N-terminal end, while the C-terminal end contains a short 
regulatory protein-fragment called endorepellin (Iozzo & Sanderson, 2011). In smooth muscle 
cells, the HS chains of perlecan are substituted with CS chains (Lord et al., 2014).  Examples 
of PGs that may occur as hybrid PGs are syndecan-1 and syndecan-3 that can carry both HS 
and CS-chains (Couchman, 2010) and aggrecan that carries both CS and KS chains (Aspberg, 
2012). 
 
Serglycin is a unique intracellular PG carrying heparin chains and/or chondroitin sulfate 
chains. Serglycin is found in secretory granules of hematopoietic cells (Schick et al. 2001).  
 
1.2.3 Glypicans  
There are six members of the human glypican family: glypican 1-6 (Filmus et al., 2008). 
Glypicans are further subdivided into two subfamilies consisting of: (a) glypican-1, -2, -4, -6 
and (b) glypican-3 and -5, with about 25% amino-acid identity between the two groups (Filmus 
et al., 2008). They carry at least one or two HS chains covalently attached to the core protein 
close to the cell membrane where the carboxyl terminal of the core protein is linked to the cell 
surface by a GPI anchor (Filmus et al., 2008). Just like other membrane associated HSPGs, 
glypicans influence growth factor signaling via the HS chains by formation of ternary 
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complexes with growth factors and corresponding growth factor receptors required for Wnt 
(Gao et al., 2014), Hedgehog (Capurro et al., 2008) and FGF (Jen, Musacchio, & Lander, 
2009) signaling. 
 
1.2.4 Syndecans  
There are four members in the human syndecan family, syndecans-1 to -4 (Fig. 2) which are 
characterized by HS or CS chains covalently attached to the ectodomain of the core protein 
(Mitsou, Multhaupt, & Couchman, 2017). Syndecan-1 and syndecan-3 may carry both HS and 
CS chains, whereas syndecan-2 and syndecan-4 exclusively have HS chains (Afratis et al., 
2017). 
Syndecan core proteins consist of a short intracellular domain, a small transmembrane domain 
and variable length extracellular domains (ectodomains) (Couchman, 2010). The cytoplasmic 
domain is subdivided into three parts: two conserved regions - C1 and C2, which are similar 
in all syndecans and are separated by one variable region (V) that is specific for each syndecan 
isoform (Couchman, 2010). The conserved region C1 is involved in endocytosis and exosome 
formation whereas C2 has a terminal amino acid sequence - EFYA region (glutamine, 
phenylalanine, tyrosine and alanine), capable of binding PDZ-domain carrying proteins 
(Cheng, Montmasson, Terradot, & Rousselle, 2016). There is formation of signaling 
complexes around the EFYA region including adaptor proteins and kinases such as Src, Rac 
and Rho. The activation of such proteins triggers important down-stream signaling pathways 
that may result into cytoskeletal reorganization, cell migration, cell survival and proliferation 
(Cheng et al., 2016).  
The tissue distribution of mammalian syndecans is developmental-stage, cell-type, and tissue-
specific (Cheng et al., 2016). Syndecan-1 and -4 have the widest distribution in the body, 
whereby syndecan-1 is expressed in epithelial cells and syndecan-4 in almost all cells. 
Syndecan-2 is expressed in endothelial, fibroblasts, liver and neuronal cells (Horiguchi et al., 
2013). Syndecan-3 has a limited distribution and is predominantly expressed by nerve and 
skeletal muscle cells (Cheng et al., 2016; Cornelison, Filla, Stanley, Rapraeger, & Olwin, 
2001).  
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Syndecans may be modified through protease/heparanase activity or internalized into the 
cytosol where they are degraded in lysosomal vesicles. In addition, translocation of syndecans 
into the nucleus has been reported (Stewart, Ramani, & Sanderson, 2015).  Proteases including 
members of the matrix metalloproteinase family cleave syndecan core proteins resulting into 
release (shedding) of the syndecan ectodomain (Manon-Jensen et al., 2010; Manon-Jensen, 
Multhaupt, & Couchman, 2013). The heparanase enzyme cleaves HS chains rendering them 
solubilized in the ECM (Stewart et al., 2015; Vlodavsky, Ilan, Naggi, & Casu, 2007; 
Vlodavsky et al., 2016). Generally, syndecans have been reported to be involved in mediating 
cell-cell, cell-ECM interactions and cell-pathogen interactions where they facilitate viral 
attachment to a cell before eventually penetrating the cell membrane (Cheng et al., 2016).  
 
Figure 2. A schematic illustration of cell surface HSPGs: syndecans and glypicans (Modified 
with permission from a review by (Couchman, 2010). 
 
1.2.5 Perlecan  
Perlecan is a large basement membrane-associated HSPG composed of five different domains 
or subunits (Cohen, Grassel, Murdoch, & Iozzo, 1993). Perlecan is the main basement 
membrane proteoglycan but can also be found in the interstitial space. It is the largest of all 
proteoglycans, with a core protein of about 500 kDa that can be modified by attachment of up 
to three HS chains estimated to be 65 kDa each (Kallunki & Tryggvason, 1992; Noonan et al., 
1991). Its five domains have various functions and are numbered I-V (Fig. 3) starting from 
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the N-terminal end to the C-terminal end (Kallunki & Tryggvason, 1992; Murdoch, Dodge, 
Cohen, Tuan, & Iozzo, 1992).  
The first domain (I) is the N-terminal end that is commonly modified by HS chains and more 
rarely with CS chains (Lord et al., 2014). Domain (I) is involved in growth factor 
sequestration, co-receptor functions and angiogenesis. The second domain (II) is involved in 
lipid retention. The third domain (III) is involved in attachment to cell surface and secretion 
into the ECM. The fourth domain (IV) is involved with scaffold formation and maintenance 
of ECM integrity. The fifth and last domain (V), also known as endorepellin, is involved in 
cell surface binding, angiogenesis inhibition (Iozzo & Sanderson, 2011), cytoskeleton 
disassembly and induction of autophagy (Goyal, Gubbiotti, Chery, Han, & Iozzo, 2016; Goyal 
et al., 2012; Gubbiotti, Neill, & Iozzo, 2017; Poluzzi et al., 2014).  
Perlecan is expressed in a wide range of tissues and involved in several physiological 
processes including cartilage morphogenesis, osteogenesis (Jochmann, Bachvarova, & 
Vortkamp, 2014), lymph node formation, lipid metabolism and cardiovascular-tissue 
development (Gubbiotti et al., 2017). Perlecan has been suggested to play a role in embryo 
implantation and placentation albeit with a significant level of functional redundancy due to 
presence of other HSPGs in the uterus (Farach-Carson & Carson, 2007). Clinically, perlecan 
is also involved in several pathological conditions such as inflammation, wound-healing and 
cancer angiogenesis that potentially define its significance in medicine as a possible drug 
target (Gubbiotti et al., 2017).  
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Figure 3. Perlecan structure. Composite scale model for intact human perlecan domains (A) 
based on available images obtained using rotary shadowing of individually expressed domains 
and atomic force microscopy. Unlike linear models, the molecule appears as a modular 
structure with both globular and extended regions (B) that support its function as an 
extracellular scaffold protein. Specific domains (A) and full-length perlecan molecule (B). 
(Adapted with permission from (Farach-Carson & Carson, 2007).   
 
1.2.6 Serglycin  
Serglycin is an intracellular PG found in secretory vesicles of various cells including mast 
cells, hematopoietic cells, inflammatory cells, as well as some tumor cells (Korpetinou et al., 
2014). Serglycin may also be secreted and become a constituent member of the ECM. The 
GAG chains that are attached to the serglycin core protein in connective tissue mast cells are 
heparin, but in other cell types such as mucosal mast cells and active macrophages heparin is 
substituted with CS (Kolset & Tveit, 2008).  
There is continuous synthesis of serglycin in inflammatory and stromal cells in a regulated 
way. Most of the serglycin synthesized by non-stimulated macrophages is degraded while that 
synthesized by the activated macrophages is secreted (Scully, Chua, Harve, Bay, & Yip, 2012; 
Uhlin-Hansen et al., 1993).  Serglycin synthesis may be upregulated by factors such as tissue 
necrosis factor, lipopolysaccharides and interleukin-1 (Imoto-Tsubakimoto et al., 2013; 




CD44 is also known as a ‘lymphocyte homing receptor’ that enables circulating lymphocytes 
to adhere to specialized endothelial cells. It is a part time proteoglycan because CD44 can exist 
with or without covalently attached HS or CS chains (Goodison, Urquidi, & Tarin, 1999). It 
is expressed by various cells including epithelial cells, monocytes and melanocytes 
(Stamenkovic, Aruffo, Amiot, & Seed, 1991). CD44 can be found in healthy human tissues 
and in some tumors (Fox et al., 1994). CD44 occurs in several isoforms due to alternative 
splicing of exons within its ectodomain (Jackson et al., 1995). CD44 is the main hyaluronan 
receptor (Aruffo, Stamenkovic, Melnick, Underhill, & Seed, 1990).  
 
1.3 Heparan sulfate biosynthesis  
The biosynthesis of HS polysaccharide chains takes place in the Golgi apparatus starting with 
the assembly of a tetrasaccharide GAG-protein linker region composed of one xylose, two 
galactose units and one GlcA (GlcA-Gal-Gal-Xyl-O) (Fig. 4) attached to a selected serine 
residue in the core protein (Busse-Wicher, Wicher, & Kusche-Gullberg, 2014; Carlsson, 
Presto, Spillmann, Lindahl, & Kjellen, 2008). The entire assembly process is catalyzed by 
specific enzymes known as glycosyltransferases which are usually named according to the 
sugar residue that is added to the growing polysaccharide chain (Sugahara & Kitagawa, 2000). 
The attachment of xylose onto the serine residue is catalyzed by a xylosyltransferase enzyme; 
addition of the first galactose by galactosyltransferase I; the second galactose by 
galactosyltransferase II, and addition of the GlcA is by the glucuronyltransferase I (Sugahara 
& Kitagawa, 2000).  
The addition of a GlcNAc residue to the tetrasaccharide linker region initiates HS chain 
elongation and is catalyzed by EXTL3 (having GlcNAc-transferase-I activity) (Busse-Wicher 
et al., 2014). The subsequent elongation of the chain by addition of alternating GlcA and 
GlcNAc residues is catalyzed by a complex of the exostosin proteins - EXT1 and EXT2, 
harboring both GlcNAc and GlcA-transferase-II activities (Busse et al., 2007) (Fig. 4). The 
HS chain polymerization is accompanied by a concomitant process of chain modification 
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reactions that start with the dual enzyme activity of the N-deacetylase/N-sulfotransferase 
(NDST). This enzyme removes N-acetyl groups from some GlcNAc residues and replaces 
them with N-sulfate groups (Cheung, Eriksson, Kusche-Gullberg, Lindhal, & Kjellen, 1996). 
This dual enzyme activity is responsible for creating intervals of N-acetylated (NA), N-
sulfated (NS) and mixture of N-acetylated and N-sulfated (NA/NS) regions throughout the 
entire length of the HS chain (Cheung et al., 1996; Pikas, Eriksson, & Kjellen, 2000).  
Due to the substrate specificity of the other HS modifying enzymes, all subsequent 
modifications occur within or in the vicinity of the N-sulfated regions (Kjellen, 2003). The 
modification by NDST is followed by activity of the C5-epimerase that switches the stereo-
chemistry of GlcA at the C-5 position into IdoA (Hagner-Mcwhirter, Lindahl, & Li, 2000). 
Subsequently, different O-sulfotransferases transfer sulfate groups to the following positions: 
the sixth position of GlcN-residues, the C-2 position of IdoA and rarely the C-2 position of 
GlcA and the C-3 position of GlcN residues (Carlsson et al., 2008; El Masri, Seffouh, Lortat-
Jacob, & Vives, 2016; Kusche-Gullberg & Kjellen, 2003). The enzymes appear to be 
expressed in a cell and tissue specific manner, with their activities presumably resulting in 
distinct HS structures characteristic for each cell and tissue type (Ledin et al., 2004). Because 
only a fraction of the potential substrates are modified at each modification step, the HS chains 
are composed of: unmodified NA-domains of -GlcA-GlcNAc-repeats; NS-domains rich in O-
sulfate groups; and NA/NS domains with mixed N-acetylated and N-sulfated GlcN residues 
(Maccarana, Sakura, Tawada, Yoshida, & Lindahl, 1996; Pikas et al., 2000).  
Further modifications of the HS chain can occur post biosynthetically by the action of 
extracellular sulfatases (Sulf1 and Sulf2) removing sulfate groups from 6-O-postions 
(Morimoto-Tomita, Uchimura, Werb, Hemmerich, & Rosen, 2002) and the heparanase 
enzymes cleaving the HS chains into smaller oligosaccharides (Hammond, Khurana, Shridhar, 
& Dredge, 2014; Vives, Seffouh, & Lortat-Jacob, 2014). 
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Figure 4. A schematic illustration of HS biosynthesis. The chain elongation from the 
tetrasaccharide linkage region is initiated by EXTL3 (and possibly EXTL2), and the 
polymerization is continued by the action of an EXT1/EXT2 complex (possibly also involving 
EXTL1). There is subsequent chain modification by NDST, C5Epi and O-sulfotransferases 
(OST) enzymes. This report focused on the chain elongating enzymes indicated in red. (Figure 
courtesy of Marion Kusche-Gullberg).  
 
1.4 The EXT-family 
The EXT acronym comes from the word exostosin which is the name used to describe an 
inherited bone disorder called hereditary multiple exostoses or osteochondromas (HME/MO) 
(Wuyts & Van Hul, 2000; L. Xu et al., 1999). This bone disorder is associated with autosomal 
dominant mutations in the gene of either EXT1 or EXT2 (Seki et al., 2001; Wuyts & Van Hul, 
2000). The two proteins are part of a family of five members that in addition to EXT1 and 
EXT2 include the exostosin-like proteins - EXTL1, EXTL2 and EXTL3. The EXTL proteins 
belong to the EXT-family based on amino acid sequence homology with EXT1 and EXT2, 
but are not associated with MO (Busse-Wicher et al., 2014).  
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The genes encoding the EXT-family of proteins are found on the following chromosomal loci: 
8q24.1 (EXT1) (Cook et al., 1993), 11p11-12 (EXT2) (Wuyts et al., 1995) and 19p (EXTL1), 
1p11-p12 (EXTL2) (Wuyts et al., 1997) and 8p12-21 (EXTL3) (Van Hul et al., 1998).  The 
expression of the EXT genes varies with the developmental stage, cell type and tissue type. 
The most widely expressed genes are EXT1, EXT2, EXTL2 and EXTL3 that are found in most 
mammalian tissues, whereas EXTL1 has a more limited expression profile (Busse-Wicher et 
al., 2014). EXTL1 is expressed in brain, heart and skeletal muscles (Wise, Clines, Massa, 
Trask, & Lovett, 1997).  
The EXT-family members are type II trans-membrane proteins with a short N-terminal 
cytoplasmic region, a trans-membrane domain, a stem region, and a large C-terminal catalytic 
domain facing the Golgi lumen (Fig. 5) (Kellokumpu, Hassinen, & Glumoff, 2016). The 
physical characteristics of EXTL proteins have been demonstrated based on the 
crystallographic structures of EXTL2 (Pedersen et al., 2003) and EXTL3 (Awad, Kjellstrom, 
Svensson Birkedal, Mani, & Logan, 2018) that exhibit similarly conserved cysteine amino 
acid residues in their catalytic domains (Zak, Crawford, & Esko, 2002). EXTL2 is the smallest 
member with 330 amino acid (a.a) residues followed by EXTL1 (676 a.a.), EXT2 (718 a.a.), 
EXT1 (746 a.a.) and EXTL3 is the largest with about 919 a.a. residues (Busse-Wicher et al., 
2014).  The physiologically active HS chain elongation unit is believed to be a hetero-complex 
of EXT1/EXT2 that adds alternating GlcNAc and GlcA to the non-reducing end of the 
growing HS chain (Busse et al., 2007). Co-expressed EXT1 and EXT2 show increased in vitro 
transferase activities compared to the activities observed for EXT1 or EXT2 alone 
(McCormick, Duncan, Goutsos, & Tufaro, 2000; Senay et al., 2000), indicating the formation 
of a Golgi-localized hetero-complex. The EXTL proteins have also been suggested to take part 
in HS biosynthesis (Busse et al., 2007; Zak et al., 2002). EXTL3 initiates HS chain elongation 
by adding the first GlcNAc residue to the GAG-protein linker region (Fig. 4) (Busse et al., 
2007). In addition, EXTL3 has been described to transfer a single GlcNAc unit to the non-
reducing end of the HS chain, as part of chain elongation or alternatively, the added GlcNAc 
may serve as a stop signal for further chain elongation (Kim et al., 2001). The roles of EXTL1 
and EXTL2 are not clearly defined, with some reports showing that EXTL2 may be involved 
in both HS chain initiation and chain termination (Moses, Oldberg, & Fransson, 1999; 
Nadanaka & Kitagawa, 2014; Nadanaka, Zhou, et al., 2013). EXTL2 has been proposed to 
terminate HS elongation by adding a GlcNAc residue to a transiently phosphorylated xylose 
on the tetrasaccharide linker region (Nadanaka, Zhou, et al., 2013). EXTL1 has been reported 
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to have some GlcNAc transferase activity linking it to HS-chain elongation (Kim et al., 2001). 
In addition to its direct role in HS elongation, EXTL3 has also been suggested to inhibit N-
sulfation by forming a complex with NDST1, resulting in the formation of HS chains with N-
unsubstituted glucosamine units (Nadanaka, Purunomo, Takeda, Tamura, & Kitagawa, 2014). 
Despite the large number of research reports about HS biosynthesis, there are still some 
unanswered questions regarding (a) the specific role of each of the EXT proteins; (b) the 
relationship between the EXT1/EXT2 hetero-complex with the other HS-biosynthetic 
enzymes; and (c) what determines the actual length of an HS chain. Although the EXT1/EXT2 
hetero-complex has been postulated as the main co-polymerase responsible for HS chain 
elongation (Busse et al., 2007), EXT2 has also been reported to interact with the HS 
modification enzymes NDST1 and NDST2 (Deligny et al., 2016; Presto et al., 2008). The role 
of EXT2 in HS chain elongation is unclear as its in vitro glycosyltransferase activities are 
weak. Due to its low transferase activities, it was speculated that EXT2 is not involved in the 
actual elongation of the HS backbone but serves as a chaperon and delivers EXT1 to the Golgi 
apparatus (Busse et al., 2007). The role of EXT2 in HS biosynthesis is further complicated by 
results indicating that EXT2 also binds to the modifying enzyme NDST1 (Presto et al., 2008). 
This has led to the suggestion that NDST1 and EXT1 compete for binding to EXT2 that acts 
as a transport protein for both enzymes from the ER to the Golgi (Presto et al., 2008). The HS 
chain elongation seems to be regulated in part by relatively undefined effects/actions of the 
HS modification enzymes. These include the increased HS-chain length after overexpression 
of NDST2 (Deligny et al., 2016; Pikas et al., 2000) and binding of EXT2 to both EXT1 and 
NDST1 (Presto et al., 2008). In addition, overexpression of C-5 epimerase in HEK293 cells 
increased HS-chain length, but co-expression of the C-5 epimerase with the 2-O-
sulfotransferase reversed this effect (Fang, Song, Lindahl, & Li, 2016). It is not known whether 
other O-sulfotransferases also influence HS-chain length. 
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Figure 5.  Golgi localized Type II membrane protein illustration. Most of the Golgi localized 
glycosyltransferases are type II membrane proteins with a short N-terminal cytoplasmic 
domain, an approx. 20 amino acid α-helical TM-domain, a stem domain and a C-terminal 
globular catalytic domain facing the lumen of the Golgi (adapted with permission from 
(Kellokumpu et al., 2016).  
1.5 Mutations in EXT/Ls using animal models  
In order to establish the functions of the various HS biosynthetic enzymes, mutational studies 
using different model organisms have been performed. Studies using both invertebrate and 
vertebrate organisms have clearly demonstrated the important role of EXT family of proteins 
in development. The loss of function of EXT family genes in the various experimental 
organisms has been reported to cause a number of abnormalities (Busse-Wicher et al., 2014), 
some of which are described here. Homozygous disruption of the Ext1 gene in mice results in 
early mortality. The homozygous mice die at gastrulation before embryonic day 9 (E9), 
whereas heterozygous mice are phenotypically normal, but with somewhat reduced bone 
 25 
length (Lin et al., 2000). Embryonic stem (ES) cells from Ext1-deficient-mouse embryos are 
unable to produce HS (Kraushaar, Yamaguchi, & Wang, 2010), and fail to differentiate into 
β3-tubulin-positive neuronal cells (Johnson et al., 2007) or hematopoietic cell-lineages 
(Holley et al., 2011). Mouse embryos with a gene trap mutation in Ext1 (hypomorphic 
mutation) express approximately 2% of wild type Ext1 mRNA and live to around embryonic 
day 14.5 (Koziel, Kunath, Kelly, & Vortkamp, 2004). Embryonic fibroblasts derived from 
these mouse embryos produce shorter HS-chain than corresponding fibroblasts from wild-type 
mice (Yamada et al., 2004). Another mouse model with a chondrocyte specific Ext1 mutation 
demonstrated that loss of Ext1-heterozygosity is contributing to characteristics typical of the 
MO phenotype (Matsumoto, Irie, Mackem, & Yamaguchi, 2010). Similarly, Ext2 deficiency 
is embryonically lethal whereas mice with a heterozygous mutation survive to maturity with 
development of multiple exostoses (Stickens, Zak, Rougier, Esko, & Werb, 2005).  
There is no known EXTL1 knockout mouse model that possibly could shed light on the 
function of EXTL1. EXTL2 knockout (KO) mice develop normally, remain healthy and fertile 
but show reduced liver regeneration ability following carbon tetrachloride (CCl4-) induced 
liver injury due to reduced hepatocyte growth factor (HGF) signaling response (Nadanaka, 
Kagiyama, & Kitagawa, 2013). Complete deletion of EXTL3 is incompatible with life and 
EXTL3 KO embryos die at about embryonic day 9 (Takahashi et al., 2009). Conditional 
knockout-mouse models have been generated to study EXTL3/HS in selected organs. In a 
podocyte-specific EXTL3 KO mouse model, there is reduced HS in the glomerular basement 
membrane but without significantly increased urinary albumin excretion (Aoki et al., 2018). 
Targeted deletion of EXTL3 in pancreatic-β cells leads to abnormal cell morphology, reduced 
cell proliferation and glucose intolerance due to defective secretion of insulin (Takahashi et 
al., 2009). 
Mutational studies in Drosophila melanogaster have also demonstrated the importance of the 
EXTs. Drosophila EXT/L orthologues have been shown to be important: tout velu (ttv, EXT1 
orthologue) in Hedgehog signaling (Bellaiche, The, & Perrimon, 1998); sister of ttv (sotv, 
EXT2)  and brother of ttv (botv, EXTL3) in wing development (Takei, Ozawa, Sato, Watanabe, 
& Tabata, 2004). Other model organisms including Caenorhabditis elegans (C. elegans) and 
zebrafish have also been used to study the impact of mutations in EXTs on morphogenesis and 
nerve tissue development (Blanchette et al., 2017). Mutations in zebrafish dackel (ext2) and 
boxer (extl3) were shown to be associated with defective axon sorting in the optic nerve tract 
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(Lee et al., 2004). There is reduced Fgf and Wint signaling in zebrafish carrying an ext2 
mutation that causes decreased HS biosynthesis (Fischer, Filipek-Gorniok, & Ledin, 2011).  
1.6 HS-protein interactions  
The HS-chains are highly negatively charged molecules that electrostatically attract positively 
charged amino acid residues (lysine and arginine) in the protein ligands (D. Xu & Esko, 2014). 
The sulfated NS-domains that are scattered along the HS chains provide the negatively charged 
binding sites for the interacting proteins and together with the carboxylic groups, contribute 
to the overall anionic nature of the HS chain (Ori, Wilkinson, & Fernig, 2011). Thus, the NS-
domains are important in preserving the functional integrity of the HS chain as they define the 
binding site for protein ligands (Esko & Selleck, 2002). The HS chains bind to a wide variety 
of so-called HS-binding proteins including: chemokines, cytokines, morphogens, growth 
factors, blood coagulation factors, proteins of the complement pathway, ECM structural 
proteins, single-pass membrane proteins and adhesion molecules (Ori et al., 2011). The ability 
of HS chains to bind soluble signaling molecules defines their co-receptor role. The HS chains 
enable bound ligands to attach to their high affinity cognate receptors and thereby influence 
cell signaling (Gallagher, 2015). The ternary structure formed between the protein ligand, its 
receptor and the HS chains stabilizes the growth factor-receptor interaction (Gallagher, 2015; 
Uniewicz et al., 2010). The best known example of this interaction is illustrated by the 
formation of the FGF2-HS-growth factor receptor ternary complex, which is involved in both 
physiological (Lin, Buff, Perrimon, & Michelson, 1999) and pathological processes (Lindahl 
& Kjellen, 2013). Interestingly, HS chains have been demonstrated to mediate the binding of 
a drug agent – trastuzumab (an antibody that binds to HER2) to its therapeutic target on the 
surface of breast cancer cells (Suarez et al., 2013).  
Factors that affect the HS-chain length and sulfation status also affect the co-receptor function 
of the HSPG molecule. This has been demonstrated through studies involving overexpression 
of the heparanase enzyme that cleaves the HS chains (Batool et al., 2017), as well as the effect 
of sulfatases that selectively remove the 6-O-sulfate groups from the HS molecule (Seffouh et 
al., 2013). Reduction in fibroblast-Ext1 expression and hence HS chain length have been 
shown to diminish FGF2-signaling, as well as reducing the ability of the cell to interact with 
the ECM (Osterholm et al., 2009). Studies have also demonstrated a reduction in the signaling 
process, when growth factors are competitively inhibited with antibodies from binding to their 
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cell surface receptors via the supporting effect of HS chains (Gao et al., 2014; Gao, Kim, & 
Ho, 2015).  
 
1.7 Human genetic disorders due to mutations in the HS 
biosynthetic enzymes 
Several disorders have been associated with specific mutations in the HS biosynthetic enzymes 
including both those involved in assembly and modification of the HS chain. Mutations in the 
gene encoding the GAG initiation enzyme, xylosyl transferase-1 (XYLT1), cause an 
autosomal recessive short stature syndrome due to reduced enzyme activity (Schreml et al., 
2014). Cardiac and joint defects have been reported in patients with a mutation in β3GALT 
(galactosyltransferase I) due to reduced synthesis of HS and CS/DS GAGs (Baasanjav et al., 
2011). GlcATI mutations resulting in reduced expression of the bilirubin UDP-
glucuronosyltransferase enzyme are associated with a chronic non-hemorrhagic liver disorder 
called Gilbert’s syndrome that manifests with jaundice (Bosma et al., 1995; Debinski et al., 
1996; Koiwai et al., 1995). Autosomal dominant heterozygous mutations in EXT1 and EXT2 
cause hereditary multiple osteochondromas (MO) (Pacifici, 2017). MO is characterized by 
benign cartilaginous tumors at the end of long bones including the femur, humerus, tibia, 
fibular, as well as ribs and hand bones (Zak et al., 2002). Mutations in EXT2 have also been 
implicated in causing another developmental disorder called Scoliosis-macrocephaly-
syndrome that is characterized by intellectual disability, hypotonia and scoliosis but without 
exostoses (Farhan et al., 2015). Mutations in EXTL3 have been reported to cause a neuro-
immuno-skeletal dysplasia syndrome characterized by developmental delay, neuronal, 
immunological and skeletal abnormalities (Guo et al., 2017; Oud et al., 2017; Volpi et al., 
2017). Missense mutations in NDST1 cause intellectual disability and other disorders such as 
postnatal growth deficiency (Reuter et al., 2014). NDST1 deficiency has also been associated 
with developmental delay, ataxia, cranial nerve palsies and respiratory problems in infancy 
(Armstrong et al., 2017). Mutations in the HS 6-O-sulfotransferase-1 (HS6ST1) have been 
associated with idiopathic hypogonadotropic hypogonadism which is characterized by 
infertility due to defective gonadotropin-releasing hormone, also as a result of impaired 
neuronal development and function (Tornberg et al., 2011).   
 
 28
1.8 HS biosynthesis enzymes in cancer.  
The involvement of the HS biosynthetic enzymes in cancer was first attributed to EXT1 and 
EXT2, both of which have been referred to as “tumor suppressor proteins” by several authors 
(Lind, Tufaro, McCormick, Lindahl, & Lidholt, 1998; McCormick et al., 2000; Ropero et al., 
2004; Senay et al., 2000). MO patients are heterozygous for a mutation in either EXT1 or 
EXT2. Although contradictory reports are present on the cellular origin of osteochondroma, 
mouse genetic models have shown that MO probably result from a somatic mutation in the 
remaining wild-type copy of the gene in selected chondrocytes (Jones et al., 2010; Matsumoto 
et al., 2010). Osteochondromas are benign tumors with a subsequent risk of transformation 
into malignant osteosarcoma or chondrosarcoma, which occurs in 2-5% of the MO patients. 
Thus EXT1 and EXT2 fit with the classical “two-hit” model characterizing tumor suppressor 
genes (Knudson, 1971). A recent study however, showed that chondrosarcoma arises from 
cells only harboring the one-allelic germ-line mutation and not the double hit ones, indicating 
that osteochondromas and the related chondrosarcomas have different initiating cells (Musso 
et al., 2015).  
Other HS biosynthetic enzymes have also been described to be differently expressed in cancer 
including NDST-4, C-5 epimerase, sulfotransferases (HS6ST-2, HS3ST and HS2ST-1), 
heparanase and sulfatases (SULF-1, SULF-2). NDST-4 has been reported to have a potential 
tumor suppressor function as loss of NDST-4 in colorectal cancer was shown to be associated 
with poor survival (Tzeng et al., 2013). The C-5 epimerase has been suggested to be a potential 
tumor suppressor in breast and lung cancer cells (Grigorieva et al., 2011; Prudnikova et al., 
2010), but a tumor promoter or a prognostic indicator of poor survival in prostate cancer 
(Rosenberg, Prudnikova, Zabarovsky, Kashuba, & Grigorieva, 2014). Expression of HS6ST-
2 is increased in colorectal cancer tissues as compared to normal tissues with a correlation to 
poor survival (Hatabe et al., 2013), which suggests that it might be a promoter of tumor 
growth. Aberrant methylation of HS3ST increases the invasive behavior of chondrosarcoma 
cells indicating a tumor suppressor role for this enzyme (Bui et al., 2010). The extracellular-
acting SULF-1 and SULF-2 that post-synthetically modify the HS chains by removing 6-O-
sulfate groups from selected GlcN residues have been implicated in tumor progression and 
metastasis (Hammond et al., 2014; Roy et al., 2017; Vives et al., 2014). An Affymetrix-
microarray analysis showed that EXT2, HS2ST-1, HPSE and SULF-2 are differently expressed 
in malignant plasma cells (Bret et al., 2009). Upregulation of HS2ST-1 is associated with better 
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survival but that of EXT1 indicates a bad prognosis in patients with multiple myeloma (Bret 
et al., 2009). The reduced expression of EXT1 and EXT2 is presumed to impair proper HS 
biosynthesis in prostate cancer and glioma (Suhovskih et al., 2014; Ushakov et al., 2017).  
 
1.9 Role of HSPGs in cancer   
HSPGs on the cell surface, in the pericellular space and in the ECM of tumors are crucial for 
tumor cell proliferation and metastasis through their effect on the cells as well as on the tumor 
microenvironment (Iozzo & Sanderson, 2011). HSPGs have diverse effects in different types 
of tumors, acting as either promotors or repressors of tumor growth (Iozzo & Sanderson, 
2011).  
The ability of HSPGs such as glypicans, syndecans and perlecan to bind a multitude of growth 
factors in the ECM via the HS chains, makes the proteoglycans a major reservoir of growth 
factors needed to promote tumor growth and metastasis (Gao et al., 2015; Roskams, De Vos, 
David, Van Damme, & Desmet, 1998). A more direct role of cell surface HSPGs in 
tumorigenesis is exemplified by syndecans that can influence cell adhesion and migration 
through physical contacts with focal adhesion proteins and cytoskeleton (Couchman, 2010). 
Syndecan-4 has been found to be necessary in the formation of stable focal adhesions 
(Elfenbein & Simons, 2013; Morgan, Humphries, & Bass, 2007) and is considered a good 
prognostic marker for cancer patients with less migratory estrogen receptor/progesterone 
receptor (ER- or PR)-positive tumor cells (Lendorf, Manon-Jensen, Kronqvist, Multhaupt, & 
Couchman, 2011). Syndecan-2 has been reported to promote migratory behavior of the triple 
negative MDA-MB-231 cells by suppressing the function of syndecan-4 (Lim & Couchman, 
2014; Lim et al., 2015). Syndecan-1 is increasingly expressed and shed by myeloma cells, 
rendering this HSPG to be an indicator of a progressive tumor disease (Khotskaya et al., 2009). 
Additionally, increased expression of syndecan-1, especially by stromal cells has been 
reported to be a poor prognostic marker in breast cancer (Barbareschi et al., 2003; Nguyen et 
al., 2013).  
Glypicans also play important roles in cancer progression, in particular glypican-3 that 
promotes hepatocellular carcinoma growth through increased Wnt signaling (Gao et al., 2014). 
There is also increased expression of glypican-1 in certain tumors such as esophageal 
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squamous cell carcinoma, pancreatic cancers and glioblastomas with a poor prognosis (Hara 
et al., 2016; Lu et al., 2017; Saito et al., 2017). In contrast, glypican-5 has been suggested to 
act as a ‘tumor suppressor’ as it prevented tumor growth in a xenograft model and inhibited 
phosphorylation of oncogenic cell surface receptor tyrosine kinase (RTK) receptors in non-
small cell lung cancer (NSCLC) cells (Guo, Wang, Zhang, & Yang, 2016). Glypican-5 is also 
described as an ‘epigenetically repressed tumor suppressor’ due to hypermethylation of its 
promotor. Glypican-5 blocks tumor growth or epithelial to mesenchymal transition (EMT) by 
inhibiting Wnt-signaling in lung adenocarcinoma cells (Wang et al., 2016).  Glypican-6 
mediates the pro-invasive and migratory effects of nuclear factor of activated T-cells (NFAT) 
in breast cancer cells by activating the JNK and p38-MAPK pathways (Yiu, Kaunisto, Chin, 
& Toker, 2011).  
The basement membrane HSPG, perlecan may promote tumor angiogenesis through its ability 
to act as a co-receptor for the pro-angiogenic growth factors FGFs and VEGF, via its HS-
chains (Gubbiotti et al., 2017; Iozzo & Sanderson, 2011; Iozzo et al., 2009; Lord et al., 2014). 
Cleavage of the C-terminal component of perlecan by L-cathepsin yields a smaller molecule 
called endorepellin. Endorepellin may exhibit anti-angiogenic or anti-proliferative effects by 
binding the integrin α2β1 resulting into dephosphorylation and deactivation of the neighboring 
receptor tyrosine kinase receptors and autophagy (Goyal et al., 2016; Gubbiotti et al., 2017; 
Poluzzi et al., 2014).   
The effect of cell surface HSPGs can be modified by enzymes secreted in the ECM that target 
either the HS chains such as heparanase (Batool et al., 2017; Vlodavsky et al., 2007; 
Vlodavsky et al., 2016) and SULFs (Frese, Milz, Dick, Lamanna, & Dierks, 2009) or core 
proteins (sheddases) (Grindel et al., 2014). The sheddases together with heparanase tend to 
potentiate the role of HSPGs in growth factor signaling, through cleavage of either the core 
protein (Ding, Lopez-Burks, Sanchez-Duran, Korc, & Lander, 2005) or the HS chains that 
become solubilized and thus release the attached growth factors (Iozzo et al., 2009). This also 
promotes tumor angiogenesis if the growth factors released are pro-angiogenic like FGF2 and 
VEGFA (Iozzo & Sanderson, 2011).  
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2. Rationale of the study  
EXT proteins are glycosyltransferases necessary for the polymerization of HS chains. In this 
study, HS biosynthesis was studied with specific focus on EXT1 and EXT2. Gene deletion 
studies in mice have shown that EXT1, EXT2 and EXTL3 are necessary for HS chain 
elongation. In vitro studies have ascribed EXTL3 and EXTL2 as initiators and/or terminators 
of HS chain polymerization. The HS chains assembled by the EXT proteins are important in 
development, homeostasis and in disease situations. Several questions remain unanswered 
about how the EXT proteins interact amongst themselves and with other HS biosynthetic 
proteins. The knowledge obtained in this study will hopefully improve our understanding of 
HS-biosynthesis and clarify on how the HS structure might change in pathological situations 
such as cancer. 
 General objective: 
To obtain more knowledge about the molecular mechanism of action of the exostosin (EXT) 
protein family in normal physiology and in cancer biology 
Specific objectives: 
A: To analyze how stromal fibroblast Ext1-expression levels affect gene expression in tumor 
cells. 
B: To determine the gene expression pattern of the EXT family of proteins in breast cancer 
cell lines and to study if or how their mRNA levels influence HS structure. 
C: To determine effect of pH on the glycosyltransferase activity of EXT1 and EXT2. 
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3. Summary of results  
Paper I 
Potential role for fibroblast Ext1-dependent heparan sulfate in regulating P311 
gene expression in A549 carcinoma cells  
In this study, we investigated how the Ext1 expression levels in stromal fibroblasts affect gene 
expression in neighboring tumor cells using 2-dimensional co-culture and 3-dimensional 
hetero-spheroid cell culture models. In these models, human A549 non-small-cell lung cancer 
cells were co-cultured with either wild type (wt) or Ext1 mutant (Ext1Gt/Gt) mouse embryonic 
fibroblasts. The Ext1Gt/Gt fibroblasts have very short HS chains and are therefore an excellent 
model for studying the influence of HS chains on cellular activities. Differential gene 
expression experiments showed that P311 expression in the tumor cells was significantly 
reduced when co-cultured with the mutant fibroblasts. Compared to the wt fibroblasts, the 
mutant fibroblasts had reduced tgf-β1 expression and TGF-β activity. Re-introduction of Ext1 
into the Ext1 deficient fibroblasts rescued tgf-β1 expression and TGF-β-activity in the 
fibroblasts and increased P311 expression in the co-cultured A549 tumor cells. Direct 
stimulation of the tumor cells with recombinant TGF-β1 increased expression of P311, 
indicating that P311 is a TGFβ1 regulated protein. To confirm that reduced expression of 
fibroblast tgf-β1 influences P311 levels in co-cultured A549 cells, we down-regulated 
fibroblast tgf-β1-levels in wt fibroblasts using siRNA. Our results show that down-regulation 
of fibroblast tgf-1 resulted in reduced P311 expression in A549 cells. Furthermore, P311 
expression was not affected when A549 cells were cultured in conditioned media isolated from 
mutated fibroblasts indicating a requirement for physical interaction between the stromal 
fibroblasts and the tumor cells. Together, these results indicate a previously unknown potential 
regulatory function of fibroblast-Ext1 on tgf-1 expression in the same cells as well as gene 




The exostosin family of glycosyltransferases: mRNA expression profiles and 
heparan sulfate structure in human breast carcinoma cell-lines  
 In this study, we investigated the mRNA expression profiles of the EXT-family members 
(EXT/L) and how their mRNA levels are reflected in HS structure of various breast cancer 
cells and a non-tumorigenic mammary gland epithelial cell line. The cell lines used included 
two triple negative breast cancer-cell lines MDA-MB-231 and HCC38. These cells lack 
estrogen receptors (ER), progesterone receptor (PR) and human epidermal growth factor 
receptor-2 (HER2). One ER/PR-positive cell line - MCF7 and one non-tumorigenic mammary 
glandular epithelial cell line - MCF10A were also studied. There was significant reduction in 
expression of all the EXT/L genes in the less invasive ER/PR-positive cell line (MCF7), 
whereas the triple negative cell lines MDA-MB-231 and HCC38 had similar EXT/L expression 
profiles, with significantly elevated EXTL2 expression as compared to all the other cell lines.  
Using the HS-specific 10E4 antibody, flow cytometry analyses showed a strong cell surface 
staining of HS for the non-tumorigenic MCF10-A cells and the triple negative breast cancer-
cell lines. In contrast, the ER/PR-positive MCF7 cell line showed weak staining for 10E4. This 
suggested that MCF7 cells had less HS as compared to the other cell lines studied. 
Cells were radiolabeled with 35S-sulfate to determine the length and fine structure of the HS 
chains. In agreement with the flow cytometry data, MCF7 had the shortest HS chains of the 
analyzed cell lines. Surprisingly, the two triple negative cell-lines MDA-MB-231 and HCC38 
that exhibited similar EXT/L expression profiles had very different chain lengths, with the 
longest chains found on MDA-MB-231 cells.  
HS disaccharide-compositional analyses showed that the major difference in the relative 
proportions of sulfated disaccharides was that MCF7 cells had a lower proportion of 2-O 
sulfated disaccharides and the highest proportion of the 6-O sulfated disaccharides as 
compared to all the other cell lines.  
The glycosyltransferase enzyme activity of the EXT proteins varied between the cell-lines 
with HCC38 cells showing a significantly higher enzyme activity compared to the rest. A 
major limitation to this study is that we were not able to quantify the amount (as µg protein) 
of the EXT proteins in the crude cell lysates and thus could not assess the specific transferase 
 34
activities in the different cell lines. This is because most of the currently available techniques 
for protein quantification such as targeted proteomics would not preserve the EXT enzymatic 
activity during the sample-preparation procedures. Therefore, enzyme activity reported in 
paper II was estimated based on the detected glycosyltransferase activity in the total crude 
protein sample. Thus, we lack accurate information in order to get a proper correlation between 
EXT-enzyme activity and HS-chain length among the different cell lines.  
 
Paper III 
 Effect of pH on the glycosyltransferase activity of EXT1 and EXT2 proteins  
In this study, we investigated the effect of pH changes on the glycosyltransferase activity of 
recombinant full-length EXT1 and EXT2. Using serum as a positive control, we performed 
glycosyltransferase assays at pH 7.4, 6.5 and 5.0 representing pH approximately similar to that 
of the endoplasmic reticulum, Golgi complex and lysosome, respectively. Our results 
indicated that there is a reduction in glycosyltransferase activity at lower pH values. There 
was an intermediate reduction in enzyme activity for the affinity-purified proteins at a Golgi 
pH of 6.5, which is a surprising result since this is considered as the optimum pH for 
glycosyltransferase activity in vivo. We also tested a non-radioactive assay-kit that quantifies 
the glycosyltransferase activity based on the amount of released inorganic phosphate from the 
leaving UDP-nucleoside of the transferase reaction. The results from using this kit indicated 
unspecific transfer of the UDP-sugars to the oligosaccharide acceptor and we thus considered 
it unsuitable for detecting the glycosyltransferase activity of EXT-proteins. 
 In brief, these results show that a reduction in pH leads to a decline in glycosyltransferase 






4.1 Methodological considerations  
The details of the methods are mentioned in the individual manuscripts, but some 
methodological considerations are explained here: 
4.1.1 Cell lines 
The reason for selecting cell lines: Cell lines are vital in providing mechanistic details of 
cellular pathways, which cannot easily be obtained from animal models, clinical data or stored 
human tissue samples. 
The Ext1 and Ext2 knockout mice are embryonically lethal (Lin et al., 2000) which makes it 
unfeasible to study mechanistic changes of these genes using in vivo KO animal models. The 
advantage of using cells with short HS chains (Ext1Gt/Gt-mutated fibroblasts) is that we were 
able to study the cellular effects of Ext1/HS deficiency without the need to use HS degradation 
chemicals or enzymes, which would exert more metabolic stress to the cells. In project I, 
human A549 lung carcinoma cells were co-cultured with either wild type or Ext1Gt/Gt-
fibroblasts. Using cells from different species gave us the opportunity to study the cross talk 
between these two major and mutually dependent components of the tumor microenvironment.  
In project II, two triple negative breast cancer cell-lines - MDA-MB-231 and HCC38 (negative 
for ER, PR and HER2 receptors), one ER/PR-positive cell line - MCF7 and one non-
tumorigenic human mammary glandular epithelial cell line - MCF10-A were studied. The 
tumor cell lines were selected based on their different carcinogenic properties.  
 
4.1.2 Gene expression: 
RTqPCR and microarray: To study differentially expressed genes in the hetero-spheroids, we 
used microarray technology in order to get an overview of the most likely affected genes in 
project I. Then we confirmed those genes that are differentially expressed in the A549 tumor 
cells using a Real time qPCR technique. Results of gene expression obtained from the 
RTqPCR may be affected by immortalization of the cells and therefore, we crosschecked our 
results against primary cells in project I. 
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4.1.3 Western blots: 
Western blotting gives a relative measure of the presence or absence of a protein of interest in 
a sample, which helps to confirm whether a particular gene has been translated. This requires 
taking into consideration the specificity of the antibodies used in immunoblotting. 
 
4.1.4 The Glycosyltransferase Assay 
The glycosyltransferase assay quantifies the transfer of single sugars to acceptor molecules. 
We used this method to determine the GlcNAc transferase activity in cells studied in projects 
II and III (Fig. 6) This assay measures EXT1 and to some degree also EXT2 enzymatic 
activities of cells. GlcA transferase activity is measured using radiolabeled UDP-GlcA and 




Figure 6. GlcNAc-TII reaction. Cell lysates or affinity captured EXT proteins were incubated 
with radiolabeled UDP-GlcNAc and [GlcA-GlcNAc]n oligosaccharide acceptors. Next, 
radiolabeled oligosaccharides were separated from unincorporated UDP-sugars by gel 
chromatography and quantified by scintillation counting.  
 
4.1.5 Metabolic labelling and Analysis of the HS- structure 
In order to study the HS-structure, we metabolically labeled cells with 35S-sulfate. The 




UDP-[3H]GlcNAc Cellular lysates/ 
EXT proteins 
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chain. This makes it possible to estimate the HS size and the composition of the disaccharide 
units within the NS domains. The procedure summarized in Figure 7. 
Summary of HS Structural Analysis Procedures  
 
 
                                       
 











Figure 7. Flow chart summarizing steps taken from 35S labeling of cells to HS-chain length 
determination and disaccharide analysis. 
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Alkali treatment to release 
labeled GAG chains from 
core proteins using NaOH 
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using a Superose-6 gel 
chromatography column 
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4.1.6 Fibroblasts TGF-β1-siRNA knockdown  
In order to confirm the paracrine effect of fibroblast-tgf-β1 on the expression of P311 in 
adjacent A549 tumor cells, we first down regulated the expression of tgf-β1 in wild type 
fibroblasts. We chose to use siRNA technique instead of CRISP-CAS9, because we aimed to 
reduce the levels of tgf-β1 gene expression comparable to the reduction observed in the 
mutated fibroblast. Due to the risk of off-target effects, we used two different siRNA primer 
pairs targeting tgf-β1 and a non-targeting control siRNA. 
 
4.1.7 Flow cytometry:  
This technique can be used to separate or sort out cells of unique characteristic features or 
surface markers for example. In the first two projects, this technique was used to identify cells 
stained with an antibody that recognizes cell surface HS-chains or cells that were over 
expressing EGFP-tagged EXT proteins following transfection. 
 
4.1.8 TGF-β-Activity Assay  
This Luciferase based assay is used to quantify the relative amount of secreted active TGF-β 
in conditioned medium extracted from fibroblasts. The assay relies on the use of transformed 
Mink lung epithelial cell line (TMLC) which is overexpressing a luciferase-fused plasminogen 
activator inhibitor-1 (PAI-1) protein. The fact that TGF-β induces the expression PAI-1, we 
added conditioned media recovered from wt or Ext1Gt/Gt-mutated fibroblasts to the TMLC cells 





4.1.9 3D- Hetero-spheroid cell culture model  
The 3D-spheroid models (or composite spheroids) used in this work were made as described 
before (Osterholm et al., 2012).  The 3D-spheroid model mimics better the 3-dimensional 
microenvironment around the tumor cells, which includes the stromal fibroblasts. This model 
has been used in our lab to demonstrate how the stromal fibroblast-Ext1 levels and HS status 
affect tumor cell migration when co-cultured. The 2D co-culture model is easier to manipulate 
and was used to study in more details how the fibroblast tgf-β1-paracrine activity was affecting 
p311 expression in the A549 tumor cells. 
 
4.1.10 Immunoprecipitation (IP)  
We used this technic in Paper 3 to purify transiently overexpressed epitope-tagged EXT1 and 
EXT2 from the respective crude cell lysates. We were able to confirm successful 
immunoprecipitation using SDS-PAGE followed by western blotting using antibodies to the 











4.2 General discussion  
The regulation of HS biosynthesis involves a combination of enzymatic activities during the 
assembly of a tetrasaccharide-linker region, chain initiation/elongation and modification. 
There are around 25 different enzymes involved in HS biosynthesis operating in the lumen of 
the Golgi complex (Prydz, 2015). The overall HS-chain structure is dependent on the 
expression of the biosynthetic enzymes, the availability of substrates and specificity of the 
enzymes in recognizing the substrates (J. P. Li & Kusche-Gullberg, 2016). HS-chain 
initiation/elongation is very important in laying the HS foundation or backbone, which 
determines the final chain structure in terms of length and distribution of various domains 
(Busse & Kusche-Gullberg, 2003; Senay et al., 2000). The HS-chain initiation/elongation 
process is catalyzed by the EXT-proteins that are encoded by the EXT-family of genes (EXT1, 
EXT2, EXTL1, EXTL2 and EXTL3) (Busse-Wicher et al., 2014). The EXT proteins form 
hetero-oligomeric complexes, which are also capable of combining with other proteins such 
as NDSTs in a larger ‘GAGosome’ complex that regulates the overall HS-biosynthesis 
(Deligny et al., 2016; McCormick et al., 2000; Presto et al., 2008). Although previous studies 
have tried to demonstrate the functions of both cloned and endogenous enzymes, some 
important questions remain unanswered. These are questions regarding the specific roles of 
individual proteins; how they interact with each other and with other biosynthetic proteins; 
and how their expression changes in pathological conditions like cancer or if their expression 
is indicative of the HS structure. The HS-chain elongation involves the transfer of a single 
nucleotide sugar (e.g. UDP-sugars like UDP-GlcA or UDP-GlcNAc) by the 
glycosyltransferase enzymes to the non-reducing end of the growing chain (Busse & Kusche-
Gullberg, 2003). Thus, there is a need to transport the UDP sugars and other important 
substrates such as PAPS, across the Golgi membrane from the cytoplasm into the lumen where 
glycosylation and sulfation of PGs (and other proteins) occur (Prydz, 2015).  An UDP-sugar 
transporter such as HFRC1 that is capable of transporting both UDP-GlcNAc and UDP-GlcA, 
but not UDP-mannose, influences the HS biosynthesis in this manner (Suda et al., 2004). The 
activity of the UDP-sugar transporters is dependent on the relative concentration of required 
UDP sugars in the cytosol and Golgi lumen that is adequate to drive the glycosyltransferase 
activity forward (Prydz, 2015; Verbert, Cacan, & Cecchelli, 1987).   
The overall aim of this study was to investigate the mechanism controlling HS chain 
elongation and structure in physiological and pathological situations. We used a combination 
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of biochemical, molecular and cell culture techniques involving both normal and tumorigenic 
cell-lines. The HSPGs influence interactions between cancer cells and the stromal 
microenvironment via HS-chains on the cell surface. The Ext1 levels and HS-chain length of 
stromal fibroblasts have been demonstrated to affect not only growth factor signaling and 
fibroblasts’ ability to interact with the ECM (Osterholm et al., 2009), but also adjacent-tumor 
cell migration and proliferation (Osterholm et al., 2012). In paper I, we discovered another 
potential role of fibroblast Ext1-dependent HS in influencing P311 gene expression in adjacent 
tumor cells by regulating tgf-β1 levels. Ext1 is essential for HS elongation (Busse et al., 2007) 
thus; its deficiency results in shorter HS chains (Osterholm et al., 2009). However, Ext1 also 
appears to regulate tgf-β1 expression and secretion in an autocrine manner. In addition, our 
results as well as previous studies seem to suggest the existence of a positive feedback-
regulatory mechanism between TGF-β1 and P311 that influences cell differentiation, 
proliferation and migration (H. Li et al., 2016; Yue et al., 2014; Zhang et al., 2016). The effect 
of fibroblast-Ext1 on tgf-β1 levels and subsequently on P311 expression in adjacent tumor 
cells might provide an explanation for the anti-proliferation and anti-migration effects 
observed previously in Ext1-mutated fibroblast/A549 hetero-spheroids (Osterholm et al., 
2012). As we also observed reduced Smad3 and Erk1/2 phosphorylation in the Ext1-mutated 
fibroblasts, another explanation for the anti-migratory effect observed previously by 
(Osterholm et al., 2012), could be that there is no enhancement or synergistic action of FGF2 
on the TGF-β-mediated cell migration (Saitoh, 2015). In addition, there is also lack of FGFR-
isoform switching from FGFR2/3 to FGFR1 (high-affinity receptor for FGF2) as suggested 
by (Shirakihara et al., 2011). Due to lack of sufficient HS-chains on the cell surface of stromal 
fibroblasts in contact with the tumor cells, the subsequent decrease in induction of both FGF2 
and TGFβ signaling result in an overall change in cell behavior. 
As a conclusion to this part, we can deduce that Ext1-dependent fibroblast-HS chains influence 
P311 expression in adjacent A549-tumor cells through paracrine TGFβ1 activity. 
In the second part (paper II), we set out to determine if the EXT/L expression profiles can be 
reflected by the HS structure in breast cancer cell lines. One reason for this investigation was 
the existence of several reports suggesting specific changes in HS structure based on the 
dysregulated mRNA levels of HS-biosynthetic enzymes in various cancers (Fernandez-Vega 
et al., 2015; Okolicsanyi et al., 2014; Suhovskih et al., 2015; Suhovskih et al., 2014; Ushakov 
et al., 2017).  
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In our study, the EXT/L expression pattern seems to reflect the differences in the tumorigenic 
characteristics of the breast cancer-cell lines (Neve et al., 2006), whereby MCF7 cells have a 
gene expression profile that is different from that of the triple negative cell lines. The 
significantly increased expression of EXTL2 in the triple negative cell-lines further highlights 
the enigma surrounding the exact role of this protein in HS chain assembly.  Bioinformatics 
data from www.proteinatlas.org shows that EXTL2 RNA is expressed in almost all types 
tumors, with the highest expression in Gliomas (8-fold compared to 3-fold in breast cancer). 
EXTL2 protein expression is also reported in almost all types of tumors, with the highest 
expression reported (approx. 100%) in endometrial, breast, ovarian, colorectal, head and neck, 
liver, stomach and prostate cancers; and the lowest expression (approx. 20%) in skin cancer 
(www.proteinatlas.org). To our knowledge there are no published papers confirming EXTL2 
expression in various cancers.  Some in vitro studies have indicated that EXTL2 can act either 
as an initiator or as a terminator of HS-chain elongation (Kitagawa, Shimakawa, & Sugahara, 
1999; Nadanaka, Zhou, et al., 2013; Okada, Nadanaka, Shoji, Tamura, & Kitagawa, 2010).  In 
contrast, another study showed that overexpression of EXTL2 in HEK293 cells did not cause 
a significant change in the HS-chain length whereas down-regulation of the EXTL2 resulted 
in longer HS chains (Katta et al., 2015). The high expression of EXTL2 in the triple negative 
cells is difficult to evaluate, as the precise role of EXTL2 in HS synthesis is unclear. It is 
neither possible to infer on if the observed high EXTL2 expression levels are reflected by 
translated protein levels nor its effect on HS biosynthesis.  
Although previous work involving silencing of EXTL3 with siRNA resulted in longer HS 
chains (Busse et al., 2007), it is not clear if the reduced EXTL3 expression observed in the 
triple negative cancer cells has a similar effect since we do not know how the levels compare 
to the cells used in (Busse et al., 2007). A very interesting result from this work is that although 
the two triple negative cell lines (MDA-MB-231 and HCC38) had similar EXT/L mRNA 
expression profiles, they exhibited completely different HS-chain length, again pointing to a 
more complicated regulation rather than simply the gene expression profiles. This might be 
due to differences in overall regulation HS biosynthesis and post-synthetic modification 
processes. In comparison however, the shorter HS chains in MCF7 cells are most probably 
due to the low EXT1 expression in this cell line, similar to that observed in the Ext1Gt/Gt cells 
and after siRNA mediated downregulation of EXT1 (Busse-Wicher et al., 2014; Busse et al., 
2007; Osterholm et al., 2009).   
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Various studies have investigated the expression of HS-biosynthetic enzymes mainly at 
mRNA levels but have not been able to show how this relates to the overall HS-structure found 
on the cancer cells. The HS binding-sites for various proteins are defined by the existence of 
sulfated regions (N- and O-sulfated domains) scattered along the entire length of the HS 
polysaccharide (J. P. Li & Kusche-Gullberg, 2016). In addition, this HS-structural 
organization is known to be modified post-synthetically by heparanase and sulfatases (SULFs) 
(Hammond et al., 2014). Increased heparanase (HPSE) expression and activity have been 
reported in various cancers (Vlodavsky et al., 2016) and we therefore, investigated if 
heparanase activity could explain the difference in the HS-chain length among our breast 
cancer-cell lines. Interestingly, we observed the highest HPSE (50kDa) protein expression in 
the MDA-MB-231 cells that have the longest HS-chains. This would suggest that differences 
in HS-chain length among the various cell-lines are probably due to cell-type specific 
regulation of HS biosynthesis rather than HS degradation by heparanase. We did not 
investigate SULF mRNA levels or activity and thus, we cannot rule out the possibility that 
increased expression of SULFs in the triple negative cells is responsible for observed lower 6-
O-sulfation in these cells.  
To conclude this part, we observed no direct correlation between EXT/L expression and HS-
structure among the breast cancer-cell lines studied, except where EXT1-levels were extremely 
low as seen in MCF7 cells. 
In the third part (paper III), we investigated the effect of different pH conditions on the 
glycosyltransferase activity of EXT1 and EXT2. We aimed at investigating if there are clear 
changes in the EXT enzyme activity as a result of the transitioning from the more neutral pH 
of ER (approx. pH 7.2) to the more acidic pH of the Golgi (approx. pH 6.5) (Rivinoja, Pujol, 
Hassinen, & Kellokumpu, 2012). We aimed at generating information that would clarify on 
whether the EXT1/EXT2 hetero-complex is formed in the ER or in the Golgi. Surprisingly, 
our in vitro assay-based results seem to contradict the widely hypothesized in vivo 
glycosyltransferase activity of EXT proteins, with suggested hetero-complex formation and 
optimum activity in the acidic pH of the Golgi (McCormick et al., 2000). Interestingly, our 
results reflect a much earlier report by Lidholt and Lindahl, which first demonstrated a similar 
trend of increasing glycosyltransferase activity with increasing pH in an in vitro setting 
(Lidholt & Lindahl, 1992). Most in vitro studies report higher activity of co-expressed 
EXT1/EXT2 than that of the individual proteins alone with assays done at the nearly neutral 
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pH of 7.4 (Busse et al., 2007; Busse & Kusche-Gullberg, 2003; Esko & Selleck, 2002; Senay 
et al., 2000). Indeed, it might be true that the optimal pH 7.4 used for most in vitro 
glycosyltransferase assays does not correspond to that of the Golgi due to constant monitoring 
of the pH by active ion pumps in the metabolizing organelle of a live cell (Demaurex, Furuya, 
D'Souza, Bonifacino, & Grinstein, 1998; Rivinoja et al., 2012). Moreover, Anti Hassinen et 
al, have also demonstrated that formation of enzymatically relevant and more active 
glycosyltransferase-hetero-complexes is dependent of the acidity of the Golgi (Hassinen et al., 
2011).   
Our results in this study are very preliminary and more repeated experiments are needed to 
draw any conclusions even though we showed that there is a decline in the EXT-
glycosyltransferase activity after decreasing the pH. 
General Conclusion:  
We have demonstrated that:  
(a)  Fibroblast-Ext1-dependent HS chains influence P311 expression in co-cultured A549 
lung adenocarcinoma cell-lines, through a combination of physical mechanisms and 
paracrine TGF-β activity. There is also a potentially new autocrine regulatory role of 
fibroblast-Ext1 on tgf-β1 expression and secretion of active TGF-β. 
(b) There is no direct correlation between EXT/L expression and HS structure in the breast 
carcinoma cell-lines and the non-tumorigenic breast epithelial cell-line investigated. 
The variations in the HS structure seem to reflect the carcinogenic properties of the 
individual breast cancer cell-lines. 
(c) Decrease in pH seems to reduce the glycosyltransferase activity of EXT1 and EXT2 
proteins in in vitro experiments. 
 45 
5. Future perspectives 
In order to unravel the exact biological significance of the observed changes in P311 
expression in the tumor cells, future studies would focus on the use of live imaging 
techniques including employing multicolor FRET, to pin down the specific location or 
destination of the translated protein in the live cell. This would help to provide 
additional information regarding the potential interactions between P311 and other 
structural or functional proteins in the cell. To quantify fibroblast-specific TGF-β1 in 
our hetero-spheroids, may require use of different fibroblasts overexpressing a tagged 
cytokine that can be exclusively quantified in this type of 3D co-culture model. 
In order to further study the correlation between the expression profiles of the EXT/L genes 
and HS structure in breast cancer cells, future studies should include investigation of 
possible unique epigenetic regulatory mechanisms. Moreover, even if the effect of 
heparanase on HS structure has already been demonstrated in other studies, it would 
be interesting to study if there are epigenetic changes that influence heparanase 
expression in the cancer cell lines used in our study. Perhaps, a modified quantification 
method using live imaging of both EXT proteins and HS chains would be a better 
alternative to obtain an accurate correlation between glycosyltransferase activity and 
HS-chain length, albeit only applicable to EXT-overexpressing cells with protein tags. 
Since there is no information regarding the exact binding sites between EXT1 and EXT2, 
mutational studies involving the different domains of these proteins are needed in order 
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